Structure and inhibition mechanisms of Mycobacterium tuberculosis essential transporter efflux protein A

A broad chemical genetic screen in Mycobacterium tuberculosis (Mtb) identified compounds (BRD-8000.3 and BRD-9327) that inhibit the essential efflux pump EfpA. To understand the mechanisms of inhibition, we determined the structures of EfpA with these inhibitors bound at 2.7-3.4 Å resolution. Our structures reveal different mechanisms of inhibition by the two inhibitors. BRD-8000.3 binds in a tunnel contacting the lipid bilayer and extending toward the central cavity to displace the fatty acid chain of a lipid molecule bound in the apo structure, suggesting its blocking of an access route for a natural lipidic substrate. Meanwhile, BRD-9327 binds in the outer vestibule without complete blockade of the substrate path to the outside, suggesting its possible inhibition of the movement necessary for alternate access of the transporter. Our results show EfpA as a potential lipid transporter, explain the basis of the synergy of these inhibitors and their potential for combination anti-tuberculosis therapy.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2025-04-01
DOI
https://doi.org/10.1038/s41467-025-58133-6
Citations
1
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
1.40

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Structure and inhibition mechanisms of Mycobacterium tuberculosis essential transporter efflux protein A

Robert Michael Stroud, Nitesh Khandelwal, Tomohiko Kawate, Andrej Săli et al.
1 citations
Nature Communications
Tuberculosis Research and Epidemiology
1.40
article

Structure and inhibition mechanisms of Mycobacterium tuberculosis essential transporter efflux protein A

Robert Michael Stroud, Nitesh Khandelwal, Tomohiko Kawate, Andrej Săli, Deborah T. Hung, Sulyman Barkho, Meghna Gupta, Ziqiang Guan, James E Gomez, Sree Ganesh Balasubramani, Ashley Y Eng
article en
1 citations

Abstract

A broad chemical genetic screen in Mycobacterium tuberculosis (Mtb) identified compounds (BRD-8000.3 and BRD-9327) that inhibit the essential efflux pump EfpA. To understand the mechanisms of inhibition, we determined the structures of EfpA with these inhibitors bound at 2.7-3.4 Å resolution. Our structures reveal different mechanisms of inhibition by the two inhibitors. BRD-8000.3 binds in a tunnel contacting the lipid bilayer and extending toward the central cavity to displace the fatty acid chain of a lipid molecule bound in the apo structure, suggesting its blocking of an access route for a natural lipidic substrate. Meanwhile, BRD-9327 binds in the outer vestibule without complete blockade of the substrate path to the outside, suggesting its possible inhibition of the movement necessary for alternate access of the transporter. Our results show EfpA as a potential lipid transporter, explain the basis of the synergy of these inhibitors and their potential for combination anti-tuberculosis therapy.

Nature CommunicationsVol. 16(1)
Broad Institute (US), Harvard University (US), Oregon Health & Science University (US), University of California, San Francisco (US), Massachusetts General Hospital (US), Duke Medical Center (US), Duke University Hospital (US), Center for Systems Biology (US)
National Institutes of Health, National Institute of General Medical Sciences
Good health and well-being
Openalex Percentile: Top 22%
Tuberculosis Research and Epidemiology
1.40
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.